Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) Other Operating Expenses (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Other Operating Expenses data on record, last reported at $21000.0 in Q3 2025.

  • For Q3 2025, Other Operating Expenses fell 34.38% year-over-year to $21000.0; the TTM value through Sep 2025 reached $111000.0, down 13.95%, while the annual FY2024 figure was $126000.0, 0.79% down from the prior year.
  • Other Operating Expenses reached $21000.0 in Q3 2025 per MBRX's latest filing, down from $28000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $44000.0 in Q1 2021 and bottomed at $21000.0 in Q3 2025.
  • Average Other Operating Expenses over 5 years is $33105.3, with a median of $32000.0 recorded in 2022.
  • Peak YoY movement for Other Operating Expenses: rose 6.67% in 2024, then tumbled 34.38% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $36000.0 in 2021, then dropped by 8.33% to $33000.0 in 2022, then increased by 3.03% to $34000.0 in 2023, then dropped by 8.82% to $31000.0 in 2024, then crashed by 32.26% to $21000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $21000.0 in Q3 2025, $28000.0 in Q2 2025, and $31000.0 in Q1 2025.